CD19 and acute lymphoblastic leukemia: Of particular interest is Blinatumomab, a CD19-directed CD3 T-cell engager [79,80] that was approved by the FDA in 2014 for the treatment of acute lymphocytic leukemia and consists of two scFvs, one engaging the CD3ε on the T cells, and the other engaging CD19 on B cells.